Effect of oral administration of kefir on serum proinflammatory cytokines on 5-FU induced oral mucositis in patients with colorectal cancer

Investigational New Drugs

Volumn 26, Issue 6, 2008, Pages 567-572

  Topuz, E ^a   Derin, D ^b   Can, G ^a   Kurklu E ^a   Cinar S ^a   Aykan, F ^a   Cevikbas A ^c   Disci R ^d   Durna, Z ^a   Sakar B ^a   Saglam, S ^a   Tanyeri, H ^a   Deniz, G ^a   Gurer U ^c   Tas F ^a   Guney, N ^a   Aydiner, A ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b Kayseri Eǧitim Ve Araştirma Hastanesi ^*  (Turkey)

^c MARMARA UNIVERSITY   (Turkey)

^d ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Kefir; Mucositis; Serum proinflammatory cytokines

Indexed keywords

ANTIINFECTIVE AGENT; FLUOROURACIL; PROBIOTIC AGENT; SODIUM CHLORIDE;

ADULT; AGAR DIFFUSION; AGED; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM CULTURE; CANCER CHEMOTHERAPY; CELL SUSPENSION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; FEMALE; HUMAN; IMMUNE RESPONSE; KEFIR; LAVAGE; MALE; MILK; MUCOSA INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STAPHYLOCOCCUS EPIDERMIDIS; STATISTICAL SIGNIFICANCE;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; CULTURED MILK PRODUCTS; CYTOKINES; FEMALE; FLUOROURACIL; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; MOUTH MUCOSA; PROSPECTIVE STUDIES; STOMATITIS; YOUNG ADULT;

EID: 53749093360     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-008-9171-y     Document Type: Article

References (23)

1. Sonis S (1997) Oral complications. In: Holland JF, Frei E III, Bast RC Jr (eds) Cancer medicine. 4th edn. Lea & Febiger, Philadelphia, pp 3255-3264
2. ST Sonis LS Elting D Keefe 2004 Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients Cancer 100 9 Suppl 1995 2025
3. A Trotti R Byhardt J Stetz 2000 Common toxicity criteria: version 2.0. An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy Int J Radiat Oncol Biol Phys 47 13 47
4. National Cancer Institute Common Terminology Criteria for Adverse Events v3.0(CTCAE) (2003) Cancer Therapy Evaluation Program. Released December 2003. http://ctep.info.nih.gov. Cited January 20, 2005
5. ST Sonis G Oster F Fuchs 2001 Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation J Clin Oncol 19 2201 2205
6. ST Sonis JP Eilers JB Epstein 1999 Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. Mucositis Study Group Cancer 85 2103 2113
7. World Health Organization (1979) Handbook for reporting results of cancer treatment. World Health Organization, Geneva, Switzerland
8. PD Hall H Benko KR Hogan 1995 The influence of serum tumor necrosis factor-alpha and interleukin-6 concentrations on nonhematologic toxicity and hematologic recovery in patients with acute myelogenous leukemia Exp Hematol 23 1256 1260
9. ST Sonis RL Peterson LJ Edwards 2000 Defining mechanisms of action of interleukin-11 on the progression of radiation-induced oral mucositis in hamsters Oral Oncol 36 373 381
10. JB Epstein S Silverman Jr DA Paggiarino 2001 Benzydamine HCl for prophylaxis of radiation-induced oral mucositis: results from a multicenter, randomized, double-blind, placebo-controlled clinical trial Cancer 92 875 885
11. S Dreizen GP Bodey M Valdivieso 1983 Chemotherapy-associated oral infections in adults with solid tumors Oral Surg Oral Med Oral Pathol 55 2 113 120
12. M Baydar M Dikilitas A Sevinc 2005 Prevention of oral mucositis due to 5-fluorouracil treatment with oral cryotherapy J Natl Med Assoc 97 8 1161 1164
13. A Cevikbas E Yemni FW Ezzedenn 1994 Antitumoral, antibacterial and antifungal activities of kefir and kefir grain Phytother Res 8 78 82
14. T Serot X Dousset J Zucca 1990 Mise en evidence et purification partielle de substances antibacteriennes produites par Leuconostoc mesenteroides et Lactobacillus plantarum isoles de grains de kefyr Microbiol Alim Nutr 8 71 76
15. CG Vinderola J Duarte D Thangavel 2005 Immunomodulating capacity of kefir J Dairy Res 72 2 195 202
16. N Furukawa A Matsuoka T Takahashi 1991 Effects of fermented milk on the delayed-type hypersensitivity response and survival in mice bearing Meth-A Anim Sci Technol 62 579 585
17. K Osada K Nagira K Teruya 1994 Enhancement of interferon-b production with sphingomyelin from fermented milk Biotherapy 7 115 123
18. J Eilers A Berger M Petersen 1988 Development, testing and application of the oral assessment guide Oncol Nurs Forum 15 325 330
19. Clinical Laboratory Standards Institute (2005) Performance standards for antimicrobial disc susceptibility tests: 15th informational supplement. Report no M100-S15 Wayne
20. G Vinderola G Perdigon J Duarte 2006 Effects of the oral administration of the exopolysaccharide produced by Lactobacillus kefiranofaciens on the gut mucosal immunity Cytokine 36 5-6 254 260
21. A DeMoreno deLeBlanc C Matar E Farnworth 2006 Study of cytokines involved in the prevention of a murine experimental breast cancer by kefir Cytokine 34 1-2 254 260
22. KL Rodrigues LRG Caputo JCT Carvalho 2005 Antimicrobial and healing activity ok kefir and kefiran extract Int J Antimicrob Agents 25 5 404 408
23. ZN Yuksekdag Y Beyath B Aslim 2004 Determination of some characteristics coccoid forms of lactic acid bacteria isolated from Turkish kefirs with natural probiotic Lebenson Wiss Technol 37 663 667